Study offers insights into COVID-19 vaccination, infection among HSCT recipients
NEW ORLEANS — Most hematopoietic stem cell transplant recipients received at least one dose of COVID-19 vaccine, according to single-institution study results presented at ASH Annual Meeting and Exposition.
The majority reported no or minimal adverse effects, and most patients with chronic graft-versus-host disease experienced no symptom worsening, results showed.
Vaccinated patients and members of their households appeared significantly less likely to contract COVID-19 than unvaccinated patients and their household members.
Healio spoke with researcher Emily C. Liang, MD, first-year hematology/oncology fellow at University of Washington and Fred Hutchinson Cancer Research Center, about the findings and the insights they offer about HSCT recipient compliance with COVID-19 vaccination and infection.
Collapse
Liang EC, et al. Abstract 378. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.